Display options
Cite
Rył A, Rotter I, Miazgowski T, et al. Metabolic syndrome and benign prostatic hyperplasia: association or coincidence?. Diabetol Metab Syndr. 2015;7:94doi: 10.1186/s13098-015-0089-1.
Rył, A., Rotter, I., Miazgowski, T., Słojewski, M., Dołęgowska, B., Lubkowska, A., & Laszczyńska, M. (2015). Metabolic syndrome and benign prostatic hyperplasia: association or coincidence?. Diabetology & metabolic syndrome, 794. https://doi.org/10.1186/s13098-015-0089-1
Rył, Aleksandra, et al. "Metabolic syndrome and benign prostatic hyperplasia: association or coincidence?." Diabetology & metabolic syndrome vol. 7 (2015): 94. doi: https://doi.org/10.1186/s13098-015-0089-1
Rył A, Rotter I, Miazgowski T, Słojewski M, Dołęgowska B, Lubkowska A, Laszczyńska M. Metabolic syndrome and benign prostatic hyperplasia: association or coincidence?. Diabetol Metab Syndr. 2015 Oct 29;7:94. doi: 10.1186/s13098-015-0089-1. eCollection 2015. PMID: 26516352; PMCID: PMC4625953.
Copy Download .nbib Format: NLM
Share it on

Diabetol Metab Syndr. 2015 Oct 29;7:94. doi: 10.1186/s13098-015-0089-1. eCollection 2015.

Metabolic syndrome and benign prostatic hyperplasia: association or coincidence?.

Diabetology & metabolic syndrome

Aleksandra Rył, Iwona Rotter, Tomasz Miazgowski, Marcin Słojewski, Barbara Dołęgowska, Anna Lubkowska, Maria Laszczyńska

Affiliations

  1. Chair and Department of Histology and Developmental Biology, Pomeranian Medical University, Szczecin, Poland.
  2. Department of Medical Rehabilitation, Pomeranian Medical University, Szczecin, Poland.
  3. Department of Hypertension and Internal Medicine, Pomeranian Medical University, Szczecin, Poland.
  4. Department of Urology and Urological Oncology, Pomeranian Medical University, Szczecin, Poland.
  5. Department of Laboratory Diagnostics and Molecular Medicine, Pomeranian Medical University, Szczecin, Poland.
  6. Department of Physical Medicine and Functional Diagnostics, Pomeranian Medical University, Szczecin, Poland.

PMID: 26516352 PMCID: PMC4625953 DOI: 10.1186/s13098-015-0089-1

Abstract

BACKGROUND: It has been suggested that individuals with metabolic syndrome (MetS) may be prone to developing benign prostatic hyperplasia (BPH), but the direction of causality remains uncertain. The objective of this cross-sectional study was to evaluate the association between BPH and MetS in men who were referred to surgery for BPH. We were interested in identifying the anthropometric, metabolic, and hormonal factors that potentially influence the risk of both conditions.

METHODS: The study was conducted on 128 males with BPH and 141 without BPH (the control group). Fasting glucose, insulin, lipid profiles, total and free testosterone, estradiol, sex-hormone binding protein (SHBG), dehydroepiandrosterone sulfate (DHEA-S), homeostasis model assessment (HOMA-IR) index, and lipid accumulation product (LAP) were all evaluated.

RESULTS: The prevalence of MetS was higher in patients with BPH than in the controls (58 vs. 41 %; P = 0.007). In comparison to the controls, patients with BPH had higher levels of cholesterol, low density lipoproteins, DHEA-S, insulin, and HOMA-IR, but lower levels of high-density lipoproteins (HDL), estradiol, and SHBG. The significant predictors of BPH were MetS (OR = 1.961), age (OR = 0.11), HDL (OR = 0.91), insulin (OR = 1.224), SHBG (OR = 0.98), and estradiol (OR = 0.978). Waist circumference and LAP inversely correlated with total and free testosterone and SHBG.

CONCLUSIONS: Our study confirmed the frequent coexistence of MetS and BPH. This association seems to be a consequence of the MetS-related metabolic derangements, changes in the sex-hormone milieu, and lowered SHBG levels.

Keywords: Benign prostatic hyperplasia; Hormones; Metabolic syndrome

References

  1. Int Urol Nephrol. 2014 Mar;46(3):499-504 - PubMed
  2. World J Urol. 2015 May;33(5):743-51 - PubMed
  3. Urology. 2014 Nov;84(5):1181-7 - PubMed
  4. J Urol. 2013 Aug;190(2):608-14 - PubMed
  5. Obesity (Silver Spring). 2010 Sep;18(9):1836-44 - PubMed
  6. Int Braz J Urol. 2014 Mar-Apr;40(2):240-6 - PubMed
  7. J Natl Cancer Inst. 2003 Aug 20;95(16):1240-4 - PubMed
  8. BJU Int. 2015 Jul;116(1):124-30 - PubMed
  9. Atherosclerosis. 2008 Feb;196(2):696-703 - PubMed
  10. Nutr Metab Cardiovasc Dis. 2005 Aug;15(4):250-4 - PubMed
  11. Urology. 2008 Sep;72(3):556-60 - PubMed
  12. Asian J Androl. 2014 Mar-Apr;16(2):295-304 - PubMed
  13. J Endocrinol Invest. 2014 Apr;37(4):313-22 - PubMed
  14. Lancet. 2005 Sep 24-30;366(9491):1059-62 - PubMed
  15. Can Urol Assoc J. 2014 Jul;8(7-8 Suppl 5):S159-61 - PubMed
  16. BJU Int. 2015 Jan;115(1):24-31 - PubMed
  17. Aging Male. 2015;18(4):207-16 - PubMed
  18. Eur Urol. 2004 Nov;46(5):547-54 - PubMed
  19. Eur Urol. 2012 Mar;61(3):560-70 - PubMed
  20. Lipids Health Dis. 2010 Sep 16;9:100 - PubMed
  21. Maturitas. 2011 Dec;70(4):395-9 - PubMed
  22. BJU Int. 2010 Dec;106(11):1700-3 - PubMed
  23. Urol Int. 2014;93(2):214-9 - PubMed
  24. Asian J Androl. 2012 Sep;14(5):773-7 - PubMed
  25. Prostate Cancer Prostatic Dis. 2013 Mar;16(1):101-6 - PubMed
  26. Curr Opin Urol. 2014 Jan;24(1):10-4 - PubMed
  27. Prostate. 2010 Jan 1;70(1):79-89 - PubMed
  28. Int J Epidemiol. 2011 Feb;40(1):189-207 - PubMed
  29. BJU Int. 2007 Aug;100(2):321-6 - PubMed
  30. Diabetes Care. 2011 Nov;34(11):2464-70 - PubMed
  31. Urology. 2001 Apr;57(4 Suppl 1):31-8 - PubMed
  32. Prostate. 2002 Dec 1;53(4):322-9 - PubMed
  33. Eur Urol. 2007 Jan;51(1):199-203; discussion 204-6 - PubMed
  34. Prostate Cancer Prostatic Dis. 2009;12(2):160-5 - PubMed
  35. Urology. 2007 Apr;69(4):708-13 - PubMed
  36. Urology. 2009 Mar;73(3):544-8 - PubMed

Publication Types